Welcure Drugs & Pharmaceuticals Ltd

Corporate Office Closure

• Discontinuation of Ahmedabad corporate office effective 14 July 2026.
• Statutory records will be transferred to the registered office.
• Business operations will continue without interruption.

Financial Performance Q3 FY26

• Revenue from operations was Rs 6,562.4 lakhs, up from Rs 883.8 lakhs YoY.
• Total income stood at Rs 6,708.83 lakhs including Rs 146.43 lakhs other income.
• Total expenses were Rs 5,429.78 lakhs, mainly driven by stock-in-trade purchases of Rs 5,413.1 lakhs.
• Profit before tax was Rs 1,136.5 lakhs, up from Rs 91.4 lakhs YoY.
• Profit after tax was Rs 850.5 lakhs, compared to Rs 41.5 lakhs in Q3 FY25.
• Basic and diluted EPS for continuing operations was Rs 0.76 per share.
• No exceptional items reported for the quarter.

Segment Performance Q3 FY26

• Agriculture segment revenue was Rs 6,562.4 lakhs, up from zero last year.
• Drugs and Pharmaceuticals segment revenue was nil, down from Rs 883.8 lakhs YoY.
• Agriculture segment EBITDA was Rs 1,136.5 lakhs versus nil last year.
• Drugs and Pharmaceuticals segment EBITDA was nil versus Rs 91.4 lakhs YoY.
• Agriculture segment PBT was Rs 1,136.5 lakhs; Drugs and Pharmaceuticals segment PBT was nil.
• Agriculture segment assets increased to Rs 36,810.02 lakhs from Rs 10,133.45 lakhs last year.
• Drugs and Pharmaceuticals segment assets declined to nil from Rs 10,133.45 lakhs YoY.
• Agriculture segment liabilities were Rs 35,684.9 lakhs; Drugs and Pharmaceuticals liabilities were nil.

Other Financial Details

• Employee benefits expense was Rs 1.4 lakhs for the quarter.
• Depreciation and amortization expense was Rs 0.5 lakhs.
• Finance costs were nil for the quarter.
• Other expenses were Rs 10.9 lakhs.

Corporate Actions

• Board approved unaudited Q3 FY26 financial results and limited review report on 12 Feb 2026.

🗓️ Meeting Details

• Board meeting scheduled for February 12, 2026, at the registered office in New Delhi.

📊 Financial Performance

• Approval of unaudited financial results for the quarter and nine months ended December 31, 2025.